- CABB sold Jayhawk Fine Chemicals to Anupam Rasayan for $150 million.
- The sale is part of CABB's strategy to focus on Pharma and Life Science.
- Jayhawk specializes in advanced intermediates and high-performance materials.
- Anupam Rasayan aims to expand its US presence and performance materials business.
Transaction Overview
The CABB Group has completed the sale of its US-based production site, Jayhawk Fine Chemicals Corporation, to Anupam Rasayan India Ltd for $150 million. This transaction involves a 100% equity stake in Jayhawk.
Strategic Shift
This divestment aligns with CABB's strategy to transition from industrial applications, electronics, and semiconductors to focus on expanding its specialties portfolio in Pharma and Life Science. The company aims to leverage high growth and margin potential from its production sites in Switzerland, Germany, and Finland.
Jayhawk's Role
Since its acquisition in 2018, Jayhawk has been a significant contributor to CABB's results, steadily increasing revenues. The company specializes in custom manufacturing of advanced intermediates, active ingredients, and high-performance materials, utilizing state-of-the-art facilities for complex chemistries.
Anupam Rasayan's Plans
Anupam Rasayan intends to strengthen its presence in the US market and expand its performance materials business. The acquisition is expected to ensure a promising future for the Jayhawk team and support its long-term growth.
